Immutep Limited Total Liabilities
Immutep Limited total liabilities. Based on the latest financial reports, Immutep Limited (YP1A) has total liabilities worth €48.30 Million EUR (≈ $56.47 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check YP1A asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immutep Limited (2017–2024)
Total liabilities of Immutep Limited from 2017 to 2024. This chart illustrates how Immutep Limited's total liabilities have evolved over time, based on quarterly financial data.
Immutep Limited Competitors by Total Liabilities
The table below lists competitors of Immutep Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Walkabout Resources Ltd
AU:WKT
|
Australia | AU$36.64 Million |
|
DMS Propertindo Tbk PT
JK:KOTA
|
Indonesia | Rp471.84 Billion |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
China | CN¥2.84 Billion |
|
Iskandar Waterfront City Bhd
KLSE:1589
|
Malaysia | RM636.26 Million |
|
PEH Wertpapier AG
F:PEH
|
Germany | €28.76 Million |
|
Green Cross Medical Science Corporation
KQ:142280
|
Korea | ₩40.86 Billion |
|
Waskita Beton Precast Tbk PT
JK:WSBP
|
Indonesia | Rp5.05 Trillion |
|
Dongbang Agro
KO:007590
|
Korea | ₩82.24 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Immutep Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Immutep Limited asset portfolio.
Liquidity & Leverage Metrics
Immutep Limited Total Liabilities Ratios Explained
Immutep Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.49 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immutep Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immutep Limited (2017–2024)
The table below shows the annual total liabilities of Immutep Limited from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | €12.06 Million ≈ $14.10 Million |
+9.82% |
| 2023-06-30 | €10.98 Million ≈ $12.84 Million |
-6.66% |
| 2022-06-30 | €11.76 Million ≈ $13.75 Million |
+34.30% |
| 2021-06-30 | €8.76 Million ≈ $10.24 Million |
-34.13% |
| 2020-06-30 | €13.30 Million ≈ $15.55 Million |
-17.68% |
| 2019-06-30 | €16.15 Million ≈ $18.89 Million |
+19.86% |
| 2018-06-30 | €13.48 Million ≈ $15.76 Million |
+59.84% |
| 2017-06-30 | €8.43 Million ≈ $9.86 Million |
-- |
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more